Halozyme Therapeutics, Inc. (HALO) short interest & options flow
NASDAQHalozyme Therapeutics enters the week after one of its worst post-earnings sessions in recent memory, with the stock down nearly 20% over five days to $102.98, while analysts scramble to reprice their conviction following a Q3 print that clearly disappointed some corners of the Street. The earnings reaction is the defining event here. The stock dropped 20.5% on November 5, the day…
HALO Morgan Stanley downgrades to Equal-Weight, raises price target to $109 from $105, citing near-term headwinds offsetting long-term pipeline potential.
- Market cap
- $11.59B
- Next earnings
- 16 Feb 2027
Key data as of 12 Nov 2026
Latest signals on HALO
- Analyst
HALO Morgan Stanley downgrades to Equal-Weight, raises price target to $109 from $105, citing near-term headwinds offsetting long-term pipeline potential.
HALO news and analysis
RSSNo long-form analysis yet for HALO. Pulse alerts and the live data picture are available on ORTEX.
Open HALO on ORTEX →Want the live picture for HALO?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for HALO — free to start on ORTEX.
Sign up for free →Open HALO on ORTEX